{"type":"trials","record":{"id":41717,"source_id":"clinicaltrials-gov","external_id":"NCT03022318","title":"Carbidopa-levodopa in Neovascular AMD","brief_summary":"From 3 large patient databases, patients diagnosed with AMD who have never taken levodopa(L-DOPA) containing medications have a mean age of diagnosis at 71 years. Patients who have been treated with L-DOPA containing medications have a mean age of diagnosis of AMD at 79 years. L-DOPA binds to GPR143 in the retinal pigment epithelium, and releases PEDF, which protects the retina and downregulates VEGF, which is the cause of neovascularization. The Investigators will evaluate the safety and tolerability of carbidopa-levodopa in patients with Neovascular AMD, and measure the effects on visual acuity and retinal abnormalities due to \"wet\" (neovascular) AMD.","overall_status":"Completed","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Snyder, Robert W., M.D., Ph.D., P.C.","enrollment":20,"countries":["United States"],"start_date":"2017-05-02","completion_date":"2020-05-04","last_update_date":"2025-09-12","source_url":"https://clinicaltrials.gov/study/NCT03022318","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 85 Years","comparator":null,"organization":"Snyder, Robert W., M.D., Ph.D., P.C.","interventions":["carbidopa-levodopa 25-100 mg tablets"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change in Best Corrected Visual Acuity — From start of study to first anti-vascular endothelial growth factor (VEGF) in…","Change in Central Retinal (Macular) Thickness — From start of study to first anti-VEGF injection (8-32 days).","Percent Change in Retinal Fluid From Baseline — From start of study to first anti-VEGF injection (8-32 days)","Treatment Emergent Adverse Events — From start of study to first anti-VEGF injection (8-32 days)"],"design_description":"NON RANDOMIZED · PARALLEL · TREATMENT · NONE","source_has_results":true},"controlled_terms":["Age-related Macular Degeneration","carbidopa-levodopa 25-100 mg tablets"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct03022318","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2017-05-02 to 2020-05-04","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years to 85 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.858Z","intervention":["carbidopa-levodopa 25-100 mg tablets"],"participants":20,"study_design":"NON RANDOMIZED · PARALLEL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change in Best Corrected Visual Acuity — From start of study to first anti-vascular endothelial growth factor (VEGF) in…","Change in Central Retinal (Macular) Thickness — From start of study to first anti-VEGF injection (8-32 days).","Percent Change in Retinal Fluid From Baseline — From start of study to first anti-VEGF injection (8-32 days)","Treatment Emergent Adverse Events — From start of study to first anti-VEGF injection (8-32 days)"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41717","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}